FDA issues premarket approval for novel digital amblyopia therapy
The FDA has granted de novo premarket approval for Luminopia One, a digital therapy for children aged 4 to 7 years with amblyopia, according to a press release from Luminopia. The therapy, which allows patients with amblyopia associated with anisometropia and/or mild strabismus to view modified TV shows and movies to improve their vision using a virtual reality headset, previously showed
Source: healio.com
